Clarma Capital

Clarma Capital focuses on injecting life into European Life Sciences startups by investing in early-stage companies at the forefront of medical device, medicinal product, and diagnostic innovation. Their team, located in London, Switzerland, Dublin, and Central Europe, is committed to nurturing breakthroughs in this dynamic sector. They aim to drive substantial growth and propel transformative change in healthcare. With a strategic approach, they navigate opportunities for impactful innovation while maintaining a clear vision for successful exits. They prioritize businesses with clearly differentiated products, working in collaboration with management teams to support the achievement of a company’s short-term and long-term business goals. Clarma Capital emphasizes a rigorous investment strategy that centers on early-stage European Life Sciences companies with regulated products, significant addressable markets, capable commercial management teams, and clearly defined exit plans, preferably by acquisitions or mergers. Clarma Capital leverages an extensive network of incubators, innovation hubs, academic institutions, and life sciences companies to identify promising ventures. They have a stringent regulatory framework promoting transparency and stability. Their value proposition includes assisting portfolio companies in securing follow-on funding through introductions to VCs and other investors, facilitating strategic partnerships and collaborations with other life sciences companies, hospitals, research institutes & industry stakeholders, helping companies improve their operational processes, cost management and scalability, supporting business development activities and assisting portfolio companies in navigating complex regulatory landscapes.

medical device, medicinal product, diagnostic innovation

Core thematic spaces, technologies, and target market segments of interest.